These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 20127712)
1. Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. Yan L; Huang H; Tang QZ; Zhu LH; Wang L; Liu C; Bian ZY; Li H J Cell Biochem; 2010 Apr; 109(6):1158-71. PubMed ID: 20127712 [TBL] [Abstract][Full Text] [Related]
2. Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. Ai W; Zhang Y; Tang QZ; Yan L; Bian ZY; Liu C; Huang H; Bai X; Yin L; Li H J Cell Biochem; 2010 Aug; 110(5):1111-22. PubMed ID: 20564207 [TBL] [Abstract][Full Text] [Related]
3. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Li HL; Wang AB; Huang Y; Liu DP; Wei C; Williams GM; Zhang CN; Liu G; Liu YQ; Hao DL; Hui RT; Lin M; Liang CC Free Radic Biol Med; 2005 Jan; 38(2):243-57. PubMed ID: 15607907 [TBL] [Abstract][Full Text] [Related]
4. Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Wang M; Zhang WB; Zhu JH; Fu GS; Zhou BQ Acta Pharmacol Sin; 2009 Aug; 30(8):1081-91. PubMed ID: 19597526 [TBL] [Abstract][Full Text] [Related]
5. Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. Cai J; Yi FF; Bian ZY; Shen DF; Yang L; Yan L; Tang QZ; Yang XC; Li H J Cell Mol Med; 2009 May; 13(5):909-25. PubMed ID: 19413885 [TBL] [Abstract][Full Text] [Related]
6. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. Shen DF; Tang QZ; Yan L; Zhang Y; Zhu LH; Wang L; Liu C; Bian ZY; Li H Br J Pharmacol; 2010 Feb; 159(4):970-81. PubMed ID: 20105174 [TBL] [Abstract][Full Text] [Related]
7. The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling. Zhu Y; Li T; Song J; Liu C; Hu Y; Que L; Ha T; Kelley J; Chen Q; Li C; Li Y Basic Res Cardiol; 2011 Sep; 106(5):787-99. PubMed ID: 21533832 [TBL] [Abstract][Full Text] [Related]
8. Hyperoside Protects Against Pressure Overload-Induced Cardiac Remodeling via the AKT Signaling Pathway. Wang X; Liu Y; Xiao L; Li L; Zhao X; Yang L; Chen N; Gao L; Zhang J Cell Physiol Biochem; 2018; 51(2):827-841. PubMed ID: 30466089 [TBL] [Abstract][Full Text] [Related]
9. Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction. Zhang Y; Zhang XF; Gao L; Liu Y; Jiang DS; Chen K; Yang Q; Fan GC; Zhang XD; Huang C Biochim Biophys Acta; 2014 Feb; 1842(2):232-44. PubMed ID: 24275554 [TBL] [Abstract][Full Text] [Related]
10. Caveolin-3 Overexpression Attenuates Cardiac Hypertrophy via Inhibition of T-type Ca2+ Current Modulated by Protein Kinase Cα in Cardiomyocytes. Markandeya YS; Phelan LJ; Woon MT; Keefe AM; Reynolds CR; August BK; Hacker TA; Roth DM; Patel HH; Balijepalli RC J Biol Chem; 2015 Sep; 290(36):22085-100. PubMed ID: 26170457 [TBL] [Abstract][Full Text] [Related]
11. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Li HJ; Yin H; Yao YY; Shen B; Bader M; Chao L; Chao J Cardiovasc Res; 2007 Jan; 73(1):130-42. PubMed ID: 17137568 [TBL] [Abstract][Full Text] [Related]
12. Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling. Huang Y; Wu D; Zhang X; Jiang M; Hu C; Lin J; Tang J; Wu L Gene; 2014 Feb; 536(2):225-31. PubMed ID: 24378234 [TBL] [Abstract][Full Text] [Related]
13. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Yagi S; Akaike M; Aihara K; Ishikawa K; Iwase T; Ikeda Y; Soeki T; Yoshida S; Sumitomo-Ueda Y; Matsumoto T; Sata M Hypertension; 2010 Apr; 55(4):918-23. PubMed ID: 20194307 [TBL] [Abstract][Full Text] [Related]
14. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. Tang Q; Cai J; Shen D; Bian Z; Yan L; Wang YX; Lan J; Zhuang GQ; Ma WZ; Wang W J Mol Med (Berl); 2009 Mar; 87(3):249-60. PubMed ID: 19096818 [TBL] [Abstract][Full Text] [Related]
15. Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy. Gao L; Huang K; Jiang DS; Liu X; Huang D; Li H; Zhang XD; Huang K Hypertension; 2015 Apr; 65(4):871-81. PubMed ID: 25646292 [TBL] [Abstract][Full Text] [Related]
16. The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. Cannon MV; Yu H; Candido WM; Dokter MM; Lindstedt EL; Silljé HH; van Gilst WH; de Boer RA Eur J Heart Fail; 2015 Mar; 17(3):273-82. PubMed ID: 25684370 [TBL] [Abstract][Full Text] [Related]